To OMX Nordic Exchange Copenhagen
Announcement No. 25-08 / Copenhagen, July 24, 2008

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

Phase IV post marketing study results for Totect® accepted by the FDA

Copenhagen, Denmark – July 24, 2008 – TopoTarget A/S (OMX: TOPO) announced that the Post Marketing Commitment to complete and submit a pharmacokinetic analysis for Totect® has been fulfilled and accepted by the FDA.

During the approval process of Totect® (trade name Savene® in the European market) - TopoTarget made a commitment to complete and submit a post-marketing population pharmacokinetic analysis to the FDA. A clinical phase IV study was conducted to examine the pharmacokinetics of a 3-day dosing regimen of Totect® efficacy in patients suffering from anthracycline extravasation. The clinical results confirmed TopoTarget's theoretical model and thus ruled out Totect® accumulation during the recommended 3-day treatment regime. The results were accepted by the FDA and TopoTarget has now fulfilled its commitment.

Today's news does not change TopoTarget's full-year financial guidance for 2008.

TopoTarget A/S

For further information, please contact:

Ulla Hald Buhl — Telephone +45 39 17 83 92
Director IR & Communications — Mobile +45 21 70 10 49

Background information

About TopoTarget
TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. The company is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors). TopoTarget has a broad cllinical pipeline with 9 products in development, including belinostat which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours where it can be used in combination with full doses of chemotherapy. The company's first marketed product Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales force in Europe and the US. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.